Oppenheimer Upgrades Ascendis Pharma to Outperform, Announces $180 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer has upgraded Ascendis Pharma (NASDAQ:ASND) from Perform to Outperform, setting a price target of $180.
September 05, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has upgraded Ascendis Pharma to Outperform with a $180 price target, indicating a positive outlook for the stock.
The upgrade from Perform to Outperform by Oppenheimer suggests increased confidence in Ascendis Pharma's future performance. The $180 price target indicates potential upside, likely leading to positive investor sentiment and a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100